Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Down 6.3% in December

Dynavax Technologies Co. (NASDAQ:DVAX) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 16,780,000 shares, a decline of 6.3% from the November 30th total of 17,900,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is currently 8.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DVAX. Franklin Resources Inc. lifted its position in shares of Dynavax Technologies by 5.7% during the third quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock worth $862,000 after acquiring an additional 4,459 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Dynavax Technologies during the 3rd quarter worth about $89,000. Sanctuary Advisors LLC boosted its stake in Dynavax Technologies by 9.1% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after purchasing an additional 1,484 shares during the period. SkyView Investment Advisors LLC purchased a new position in Dynavax Technologies during the 3rd quarter valued at about $127,000. Finally, Barclays PLC increased its position in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Performance

Shares of DVAX traded down $0.06 during trading hours on Wednesday, hitting $12.77. The company’s stock had a trading volume of 948,101 shares, compared to its average volume of 2,094,966. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 98.24 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The business has a 50 day simple moving average of $12.52 and a two-hundred day simple moving average of $11.55. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $15.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.